Amedisys, Inc. (AMED) Thwomps Q2 Profit Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Amedisys (AMED) Moves to Highs of Session Following Better-than-Expected Results
July 30, 2014 12:22 PM EDTAmedisys (NASDAQ: AMED) is gaining momentum amid today's stronger-than-expected Q2 results. Shares are now up 17% on heavy volume.
Amedisys, Inc. (NASDAQ: AMED) reported Q2 EPS of $0.25, $0.21 better than the analyst estimate of $0.04. Revenue for the quarter came in at $305... More
